Rapid Discovery of Potent anti-PD-L1 Antibodies Enabled by Single Plasma B Cell Cloning on the Beacon Platform and Epitope Binning with the Carterra LSA

Presented by Dr. Shrieen Khan, Senior Director of Biologics at ChemPartner

Abstract:

  • Antibody discovery in weeks versus years
  • Isolate, culture, and assay tens of thousands of single cells with the Beacon platform
  • Survey the epitope landscape of your antibody panel at the earliest stages of discovery with the Carterra LSA

PD-L1 is a key inhibitor of T cell activation that is often over-expressed in cancer to escape immune surveillance and promote tumor progression. Blocking antibodies against PD-L1 or its receptor, PD-1, have shown significant clinical benefit in some patients with PD-L1 expressing tumors. Hence, there is great interest in generating therapeutic antibodies against these targets to counteract the immune suppression mechanism that tumors rely on for survival.

Epitope binning studies on the Carterra LSA revealed that hybridoma antibodies covered more diverse epitope regions but potency in functional assays was weaker across all bins while B Cell Cloning antibodies were concentrated in fewer epitope bins that represented greater potency.

Our data show that plasma B cells secreting functional antibody candidates can be rapidly identified on the Beacon compared to several months for a hybridoma campaign and screening those antibodies for epitope specificity and affinity can be completed in just days on the Carterra LSA, thus substantially accelerating the antibody discovery process.

Keep watching…

Drug Discovery Advanced with Modern Externalized Models

Drug Discovery Advanced with Modern Externalized Models

Presented by Dr. Sarah Lively, Vice President of Innovation and New Technology at ChemPartner Abstract: The world of external support to advance drug discovery has changed dramatically in the last 20 years. We are now in a position where we can truly rely on external...

Drugging the Undruggable Cancer Targets

Drugging the Undruggable Cancer Targets

Presented by Dr. Ming Liu, Senior Vice President of Biology and Pharmacology at ChemPartner Abstract: Cancer is a multifactorial disease, and its genesis and progression are extremely complex. The scope of precision oncology is rapidly expanding to address previously...

Headquarters

1F & 3F, Block A
2829 JinKe Road
Zhangjiang Hi-Tech Park
PuDong New Area
Shanghai China, 201203

w

Contact Us

China: +86 21 5132 0088
US: +1 650 419 9974
Europe: +45 4586 9000
Japan: +81 03 5403 6975

contact@chempartner.com